Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
1,048.5 GBX | +1.75% | +1.26% | -5.50% |
Dec. 06 | Smith+Nephew Announces Board Changes | CI |
Dec. 05 | CBI appoints former Serco boss Rupert Soames as new president | AN |
Financials (USD)
Sales 2023 * | 5.54B | Sales 2024 * | 5.81B | Capitalization | 11.3B |
---|---|---|---|---|---|
Net income 2023 * | 452M | Net income 2024 * | 614M | EV / Sales 2023 * | 2,50x |
Net Debt 2023 * | 2.54B | Net Debt 2024 * | 2.33B | EV / Sales 2024 * | 2,34x |
P/E ratio 2023 * | 26,5x | P/E ratio 2024 * | 19,0x | Employees | 19,000 |
Yield 2023 * | 2,81% | Yield 2024 * | 3,06% | Free-Float | 99.31% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +0.99% | ||
1 week | +0.58% | ||
Current month | +1.76% | ||
1 month | +5.12% | ||
3 months | -2.39% | ||
6 months | -12.99% | ||
Current year | -6.13% |
1 week
1 015.00
1 046.50

1 month
983.20
1 046.50

Current year
887.00
1 316.75

1 year
887.00
1 316.75

3 years
887.00
1 681.50

5 years
887.00
2 023.00

10 years
824.50
2 023.00

Managers | Title | Age | Since |
---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 2022 |
Director of Finance/CFO | 52 | 2020 | |
Alison Parkes
CMP | Compliance Officer | - | 1999 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 64 | 2017 |
Director/Board Member | 59 | 2014 | |
Rick Medlock
BRD | Director/Board Member | 63 | 2020 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.35% | 118 M€ | +5.30% | ||
1.79% | 9 M€ | -3.65% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.54% | 31 M€ | +5.97% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-08 | 1,048.5 | +1.75% | 1 744 167 |
23-12-07 | 1,030.5 | +0.19% | 3,363,321 |
23-12-06 | 1,028.5 | +0.29% | 2,044,867 |
23-12-05 | 1,025.5 | -0.77% | 2,672,238 |
23-12-04 | 1,033.5 | -0.19% | 2,720,874 |
Delayed Quote London Stock Exchange, December 08, 2023 at 06:37 am EST
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipments. Net sales break down by activity sector as follows:
- orthopedic surgery (40.5%): primarily orthopedic implants (hips, knees and shoulders) ;
- sports medicine, arthroscopy and cervicofacial surgery (30.5%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (29%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53% of net sales.
Calendar
2024-02-27
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy

Mean consensus
BUY
Number of Analysts
18
Last Close Price
12.96USD
Average target price
16.19USD
Spread / Average Target
+24.91%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.13% | 11 302 M $ | |
+18.36% | 110 B $ | |
-50.46% | 8 477 M $ | |
-36.12% | 4 750 M $ | |
+43.91% | 3 066 M $ | |
-7.44% | 2 932 M $ | |
-5.72% | 2 755 M $ | |
0.00% | 2 466 M $ | |
+15.78% | 2 283 M $ | |
+1.84% | 1 939 M $ |